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Respiratory viruses discovered in the 21st century and human herpes viruses (N=13) were seldom (4/50) detected in our cystic fibrosis patients
although exacerbation frequency (7.75±2.9/a versus 4.45±2.1/a; p=0.03) and colonization with Aspergillus fumigatus (RR: 2.6; CI95: 1.8–3.7),
Pseudomonas aeruginosa (RR: 1.84; CI95: 1.4–2.4), and Staphylococcus aureus (RR: 1.5; CI95: 1.2–1.9) including MRSA (RR: 4.6; CI95: 1.3–
16.6) were associated with virus positivity. Further studies should clarify whether this finding reflects non-specific colonization (human
Bocavirus) or reactivation (Epstein-Barr virus) or rather an acceleration of lung tissue inflammation.
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Respiratory infections caused by common respiratory viruses
are associatedwith an increase inmorbidity in patients with cystic
fibrosis (CF) [1–3]. The role of novel respiratory viruses (RVs)
and human herpes viruses (HHVs) for acute pulmonary
exacerbations in CF patients is currently unknown.
2. Methods
This prospective study investigated the role of eight novel RVs
and five HHVs in patients with CF. Detailed patients'
characteristics, clinical disease patterns, as well as pulmonary
bacterial and fungal colonization patterns in the CF patients were
included in order to conduct a risk factor analysis.⁎ Corresponding author. Department of Infection Control and Infectious
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doi:10.1016/j.jcf.2010.02.002Respiratory specimens (sputum) consecutively sampled at the
University Hospital Aachen from 07/07 to 06/08 of 50 CF patients
were analyzed by nucleic acid amplification technologies (PCR;
RT-PCR) for the presence of 13 viruses (human Cytomegalovirus,
Epstein-Barr virus (EBV), Herpes simplex virus 1+2, Varizella
zoster virus, human bocavirus (HBoV), human coronaviruses
(229E, OC43, HKU1, NL63), human metapneumovirus, and
human polyomaviruses (KIPyV, WUPyV)). Specimens were
obtained routinely (2/3) and during exacerbation (1/3). For a
summary of the key characteristics of the CF patients, see Table 1.
Clinical and microbial colonization data of the patients were
analyzed statistically using the Mann–Whitney U test; for
associations the risk ratios (RR) including 95% confidence
intervals were given.
3. Results
HBoV DNA was detected in 1 patient (2%) and EBV DNA
in 3 patients (6%) resulting in a positivity rate of 8%. Viral loads
were 1.5×10E2 genome equivalents (geq)/ml for HBoV andd by Elsevier B.V. All rights reserved.
Table 1
Characteristics of the CF patients (N=50).
Parameter Mean±SD (range)
Age (years) 25±12 (1–67)
Height (m) 1.68±0.1 (1.18–1.88)
Weight (kg) 60±16 (20–140)
BMI a 21.3±5.5 (14.4–52.1)
Shwachman Score 60±13 (40–75)
FEV-1 b (l) c 2.1±1.0 (0.47–4.20)
Comorbidity Frequency (%)
O2 inhalation therapy 13/50 (26)
ABPAd 6/50 (12)
DIOS e 6/50 (12)
Pancreatic insufficiency (exocrine) 46/50 (92)
Biliary cirrhosis 4/50 (8)
OLTX f 2/50 (4)
Diabetes mellitus 14/50 (28)
Diabetes insipidus 5/50 (10)
Mutations Frequency (%)
dF508/dF508 20/50 (40)
dF508/R553X 2/50 (4)
dF508/not dF508, not R553X 7/50 (14)
dF508/not—determined 9/50 (18)
R553X/R553X 2/50 (4)
R553X/not dF508, not R553X 1/50 (2)
Others 2/50 (4)
Not determined 7/50 (14)
a BMI: body mass index.
b FEV-1: forced expiratory volume.
c Data available only for 49 patients.
d ABPA: allergic bronchopulmonary aspergillosis.
e DIOS: distal intestinal obstructive syndrome.
f OLTX: orthotopic liver transplantation.
Table 2
Clinical and microbial data of the CF patients.
Virus-negative
patients (n=46)
Virus-positive
patients (n=4)
Associations/
differences
Age (range) 25±12 (1–68) 19±8 (11–29) ns a
Gender (m:f) 25:21 3:1 ns a
Exacerbations b/year (SD) 4.45 (±2.9) 7.75 (±2.1) p=0.03 a
Colonization (%) with
S. aureus 30 (65%) 4 (100%) RRc: 1.53
(CI95: 1.24–1.89)
MRSA 5 (11%) 2 (50%) RRc: 4.60
(CI95: 1.28–16.59)
Ps. aeruginosa 25 (54%) 4 (100%) RRc: 1.84
(CI95: 1.41–2.40)
Enterobacteriaceae 15 (33%) 0 (0%) ns c
H. influenzae 9 (20%) 0 (0%) ns c
Alcaligenaceae 9 (20%) 0 (0%) ns c
S. maltophilia 7 (15%) 0 (0%) ns c
Aspergillus fumigatus 18 (39%) 4 (100%) RRc: 2.56
(CI95: 1.78–3.66)
Shwachman Score 60 (±13) 61 (±13) ns a
BMI d 21 (5.6) 21 (3.5) ns a
Mutation: not dF508/
dF508
19 (41%) 3 (75%) ns c
Mutation: not dF508/…
or R553X/…
1 (2%) 1 (25%) ns c
ABPAe 5 (11%) 1 (25%) ns c
D. mellitus and/or
D. insipidus
13/5 (28/11%) 0/0 (0/0%) ns c
Pancreatic insufficiency 42 (91%) 4 (100%) ns c
a Mann–Whitney U test.
b Exacerbation (definition): consultation of the physician because of acute
pulmonary deterioration suggestive for infection.
c RR: risk ratio; CI95: 95% confidence interval.
d BMI: body mass index.
e ABPA: allergic bronchopulmonary aspergillosis.
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Interestingly, patients tested positive for viral DNA had suffered
significantly more pulmonary exacerbations during the preced-
ing year (7.75, SD: 2.06 vs. 4.45, SD: 2.92; p=0.03).
Furthermore, all four virus-positive patients were colonized
with Aspergillus fumigatus (RR: 2.56; CI95: 1.78–3.66);
Pseudomonas aeruginosa (RR: 1.84; CI95: 1.41–2.40), and
Staphylococcus aureus (RR: 1.53; CI95: 1.24–1.89) and these
patients were significantly more often positive for MRSA (RR:
4.6; CI95: 1.28–16.59). For further clinical and microbial data
of the CF patients, see Table 2.
4. Conclusions
Common respiratory viruses like respiratory syncytial virus
(RSV), influenza viruses, and adenoviruses have been shown to
increase morbidity in CF patients [1]. Although CF patients do
not contract respiratory infections any more frequently than
patients without CF, when they do, these infections seem to
have a greater impact on morbidity of CF patients compared to
patients without CF [1,4,5]. During the last decade, HHVs were
increasingly recognized as respiratory pathogens and since then
several novel RVs have been discovered [6]. However, whether
these novel viruses play a pathogenic or passenger role in
regards to respiratory diseases is still an ongoing debate [7].Patients only tested positive for 2 of the 13 viruses (HBoV=1,
EBV=3). This detection rate of 8% is known to be similarly low
in non-CF patients indicating that the 13 viruses tested for do
not frequently account for most pulmonary exacerbations in
patients with CF [6,8]. Retrospective studies report that HBoV
is most prevalent in infants up to the age of 2 years [7]. It should
also be borne in mind that most of respiratory virus infections
occur during childhood and therefore, age may be the most
important risk factor [6,9]. Thus, as our cohort consisted of
mostly adults, we cannot exclude the possibility that age effects
may have biased our results. Previous investigations demon-
strated a higher frequency of pulmonary exacerbations for
common respiratory viruses like RSV [1,4,10]. In line with
these results, we found that the pulmonary exacerbation
frequency was significantly associated with virus positivity in
this study. However, we did not detect any deterioration of the
Shwachman Score or a decline of FEV1 as shown for common
respiratory viruses [1,4,10,11]. Moreover, our results indicate
an association of virus positivity with colonization by A.
fumigatus, P. aeruginosa, and Staphylococcus species (includ-
ing MRSA). For other well-known respiratory viruses, an
association with several of the same bacterial pathogens has
been previously suggested [1,11,12]. A limitation is the small
number of CF patients participating in our study. Further studies
236 S. Scheithauer et al. / Journal of Cystic Fibrosis 9 (2010) 234–236should clarify whether our findings reflect a non-specific
colonization (HBoV) or reactivation (EBV) in an otherwise
severely infected organ or if these viral infections worsen lung
tissue inflammation and thus accelerate the progression of lung
disease in CF.
Results were partly presented at the 61st Annual Meeting of
the German Society of Microbiology and Hygiene (DGHM) in
Göttingen, Germany (20–23 September 2009)[13].
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